8818s Search Results


rap1 assay  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc rap1 assay
a , Schematic of RNA-seq and ChIP–seq performed in the induction phase (day 14) on R-VECs and control ECs. b , RNA-seq of R-VECs or control HUVECs in stage 1 (2D monolayers). GO term analysis was performed on differentially expressed genes. GO categories are ordered on the basis of the number of differentially expressed genes. Heat maps for GO categories in red are presented in Fig. 2c and Extended Fig. . ECM, extracellular matrix; Pos. reg., positive regulation. c , Heat map of genes in one top GO category. Values are log 2 -normalized counts per million (CPM), centred and scaled by row. ETV2 binding from ChIP–seq at the promoter of each differentially expressed gene is shown in the yellow-and-green heat map (left). d , Heat map of 490 differentially expressed genes across ECs of different tissues (stage 1, induction phase) upon ETV2 expression. Tissue-adjusted log 2 -transformed CPM, centred and scaled by row. e , ETV2 ChIP–seq in R-VECs during the induction phase (stage 1; 2D) using an anti-Flag antibody or mouse IgG as control. ChIP for H3K4me3, H3K27ac and H3K27me3 was performed in both control ECs and R-VECs at stage 1. Enriched regions were analysed by ChIP–seq. Horizontal bars underneath peaks represent significantly changed regions. Promoter regions bound by ETV2 are highlighted in cream. Track range ETV2/K27me3/K27ac, 0–0.3; K4me3/input/IgG, 0–1. f , Western blot for active <t>RAP1–GTP</t> compared to total RAP1 input for stage 1 2D control ECs (HUVECs) and R-VECs (HUVEC-ETV2). The quantification of RAP1–GTP compared to total RAP1 is shown below the blot and presented as mean ± s.e.m. g , Quantification of R-VEC vessel formation after treatment with RAP1 inhibitor or dimethyl sulfoxide (DMSO). h , Z -stack confocal images and electron microscopy images of R-VEC vessels treated with RAP1 inhibitor or DMSO at four weeks. Red circles indicate orthogonal cross-sections. Scale bars, 5 μm (top); 2 μm (bottom). Data are mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01. For statistics, see Supplementary Data .
Rap1 Assay, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/8818s/Active+Rap1+Detection+Kit/pmc07480005-299-18-20
Average 93 stars, based on 1 article reviews
rap1 assay - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
krt23 mouse monoclonal antibody  (OriGene)
N/A
KRT23 mouse monoclonal antibody clone OTI3F2 formerly 3F2
   Buy from Supplier
phf21b  (Cyagen Biosciences)
N/A
   Buy from Supplier
rab 7l1 shrna plasmid  (Santa Cruz Biotechnology)
N/A
Gene Silencers generally consist of pools of three to five target-specific 19-25 nucleotide sequences in length. For independent verification of Rab 7L1 gene silencing results, individual duplex components or plasmids are also available upon request.
   Buy from Supplier
mia3 shrna plasmid  (Santa Cruz Biotechnology)
N/A
Target species: human. Gene Silencers generally consist of pools of three to five target-specific 19-25 nucleotide sequences in length. For independent verification of MIA3 gene silencing results, individual duplex components or plasmids are also available
   Buy from Supplier
2700049a03rik shrna plasmid  (Santa Cruz Biotechnology)
N/A
Target species: mouse. Gene Silencers generally consist of pools of three to five target-specific 19-25 nucleotide sequences in length. For independent verification of 2700049A03Rik gene silencing results, individual duplex components or plasmids are also available
   Buy from Supplier
or4f52  (Cyagen Biosciences)
N/A
   Buy from Supplier
arp-1 shrna plasmid  (Santa Cruz Biotechnology)
N/A
Gene Silencers generally consist of pools of three to five target-specific 19-25 nucleotide sequences in length. For independent verification of ARP-1 gene silencing results, individual duplex components or plasmids are also available upon request. Suitable
   Buy from Supplier

Image Search Results


a , Schematic of RNA-seq and ChIP–seq performed in the induction phase (day 14) on R-VECs and control ECs. b , RNA-seq of R-VECs or control HUVECs in stage 1 (2D monolayers). GO term analysis was performed on differentially expressed genes. GO categories are ordered on the basis of the number of differentially expressed genes. Heat maps for GO categories in red are presented in Fig. 2c and Extended Fig. . ECM, extracellular matrix; Pos. reg., positive regulation. c , Heat map of genes in one top GO category. Values are log 2 -normalized counts per million (CPM), centred and scaled by row. ETV2 binding from ChIP–seq at the promoter of each differentially expressed gene is shown in the yellow-and-green heat map (left). d , Heat map of 490 differentially expressed genes across ECs of different tissues (stage 1, induction phase) upon ETV2 expression. Tissue-adjusted log 2 -transformed CPM, centred and scaled by row. e , ETV2 ChIP–seq in R-VECs during the induction phase (stage 1; 2D) using an anti-Flag antibody or mouse IgG as control. ChIP for H3K4me3, H3K27ac and H3K27me3 was performed in both control ECs and R-VECs at stage 1. Enriched regions were analysed by ChIP–seq. Horizontal bars underneath peaks represent significantly changed regions. Promoter regions bound by ETV2 are highlighted in cream. Track range ETV2/K27me3/K27ac, 0–0.3; K4me3/input/IgG, 0–1. f , Western blot for active RAP1–GTP compared to total RAP1 input for stage 1 2D control ECs (HUVECs) and R-VECs (HUVEC-ETV2). The quantification of RAP1–GTP compared to total RAP1 is shown below the blot and presented as mean ± s.e.m. g , Quantification of R-VEC vessel formation after treatment with RAP1 inhibitor or dimethyl sulfoxide (DMSO). h , Z -stack confocal images and electron microscopy images of R-VEC vessels treated with RAP1 inhibitor or DMSO at four weeks. Red circles indicate orthogonal cross-sections. Scale bars, 5 μm (top); 2 μm (bottom). Data are mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01. For statistics, see Supplementary Data .

Journal: Nature

Article Title: Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis

doi: 10.1038/s41586-020-2712-z

Figure Lengend Snippet: a , Schematic of RNA-seq and ChIP–seq performed in the induction phase (day 14) on R-VECs and control ECs. b , RNA-seq of R-VECs or control HUVECs in stage 1 (2D monolayers). GO term analysis was performed on differentially expressed genes. GO categories are ordered on the basis of the number of differentially expressed genes. Heat maps for GO categories in red are presented in Fig. 2c and Extended Fig. . ECM, extracellular matrix; Pos. reg., positive regulation. c , Heat map of genes in one top GO category. Values are log 2 -normalized counts per million (CPM), centred and scaled by row. ETV2 binding from ChIP–seq at the promoter of each differentially expressed gene is shown in the yellow-and-green heat map (left). d , Heat map of 490 differentially expressed genes across ECs of different tissues (stage 1, induction phase) upon ETV2 expression. Tissue-adjusted log 2 -transformed CPM, centred and scaled by row. e , ETV2 ChIP–seq in R-VECs during the induction phase (stage 1; 2D) using an anti-Flag antibody or mouse IgG as control. ChIP for H3K4me3, H3K27ac and H3K27me3 was performed in both control ECs and R-VECs at stage 1. Enriched regions were analysed by ChIP–seq. Horizontal bars underneath peaks represent significantly changed regions. Promoter regions bound by ETV2 are highlighted in cream. Track range ETV2/K27me3/K27ac, 0–0.3; K4me3/input/IgG, 0–1. f , Western blot for active RAP1–GTP compared to total RAP1 input for stage 1 2D control ECs (HUVECs) and R-VECs (HUVEC-ETV2). The quantification of RAP1–GTP compared to total RAP1 is shown below the blot and presented as mean ± s.e.m. g , Quantification of R-VEC vessel formation after treatment with RAP1 inhibitor or dimethyl sulfoxide (DMSO). h , Z -stack confocal images and electron microscopy images of R-VEC vessels treated with RAP1 inhibitor or DMSO at four weeks. Red circles indicate orthogonal cross-sections. Scale bars, 5 μm (top); 2 μm (bottom). Data are mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01. For statistics, see Supplementary Data .

Article Snippet: A 10-cm plate of either HUVECs or ETV2-transduced HUVECs (flat 2D induction stage) was used for the active RAP1 assay (Cell Signaling, 8818S) according to the manufacturer’s guidelines for the kit.

Techniques: RNA Sequencing, ChIP-sequencing, Control, Binding Assay, Expressing, Transformation Assay, Cream, Western Blot, Electron Microscopy